GRCL Key Statistics, Chart & Performance
The current stock price of GRCL is 10.25 USD. In the past month the price increased by 1.59%. In the past year, price increased by 412.5%.
GRCL Latest News, Press Relases and Analysis
GRCL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About GRCL
Company Profile
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Company Info
GRACELL BIOTECHNOLOGIES-ADR
Building 3, 418 Guilin Road, Xuhui District
Shanghai SHANGHAI 215123 CN
CEO: William Wei Cao
Employees: 314
Phone: 862164031522
GRACELL BIOTECHNOLOGIES-ADR / GRCL FAQ
What does GRACELL BIOTECHNOLOGIES-ADR do?
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 314 full-time employees. The company went IPO on 2021-01-08. The firm is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The firm is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
Can you provide the latest stock price for GRACELL BIOTECHNOLOGIES-ADR?
The current stock price of GRCL is 10.25 USD. The price increased by 0.05% in the last trading session.
Does GRCL stock pay dividends?
GRCL does not pay a dividend.
How is the ChartMill rating for GRACELL BIOTECHNOLOGIES-ADR?
GRCL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRCL.
What is the employee count for GRCL stock?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) currently has 314 employees.
What is GRACELL BIOTECHNOLOGIES-ADR worth?
GRACELL BIOTECHNOLOGIES-ADR (GRCL) has a market capitalization of 989.87M USD. This makes GRCL a Small Cap stock.
GRCL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GRCL. When comparing the yearly performance of all stocks, GRCL is one of the better performing stocks in the market, outperforming 99.35% of all stocks.
GRCL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRCL. While GRCL seems to be doing ok healthwise, there are quite some concerns on its profitability.
GRCL Financial Highlights
Over the last trailing twelve months GRCL reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.64% | ||
| ROE | -52.9% | ||
| Debt/Equity | 0.12 |
GRCL Forecast & Estimates
15 analysts have analysed GRCL and the average price target is 10.76 USD. This implies a price increase of 4.99% is expected in the next year compared to the current price of 10.25.